Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 3/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.61 |
| ▸ | WNT3A | P56704 | 2/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | CA4 | P22748 | 1/20 | 0.59 |
| ▸ | CA6 | P23280 | 1/20 | 0.59 |
| ▸ | CA7 | P43166 | 1/20 | 0.59 |
| ▸ | TPMT | P51580 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11599111 | 0.93 | MAPT (0.55) | MAPTALDH1A1SMN1; SMN2GAAMEN1 | |
| SCHEMBL1659363 | 0.91 | MAPT (0.71) | MAPTALDH1A1SMN1; SMN2GAAMEN1 | |
| SCHEMBL11045656 | 0.89 | MAPT (0.61) | MAPTALDH1A1SMN1; SMN2GAAMEN1 | |
| SCHEMBL16627198 | 0.86 | TAS1R3 (0.54) | MAPTALDH1A1SMN1; SMN2GAAMEN1 | |
| SCHEMBL3861897 | 0.86 | MEN1 (0.64) | MAPTALDH1A1SMN1; SMN2GAAMEN1 | |
| SCHEMBL30629388 | 0.86 | CA12 (0.65) | MAPTALDH1A1SMN1; SMN2GAAMEN1 | |
| SCHEMBL7380780 | 0.86 | MAPT (0.61) | MAPTALDH1A1SMN1; SMN2GAAMEN1 | |
| SCHEMBL4438295 | 0.86 | CA12 (0.65) | MAPTALDH1A1SMN1; SMN2GAAMEN1 | |
| SCHEMBL16376271 | 0.85 | HTT (0.63) | MAPTALDH1A1SMN1; SMN2GAAMEN1 | |
| SCHEMBL10920479 | 0.85 | ALDH1A1 (0.65) | MAPTALDH1A1SMN1; SMN2GAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2024-02-29 | — | — | US | disclosed |
| US-11753407-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20180105526-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC (US) | 2018-04-19 | — | — | US | disclosed |
| US-9879007-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170129885-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2017-05-11 | — | — | US | disclosed |
| US-9586955-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20150005289-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2015-01-01 | — | — | US | disclosed |
| US-20120094987-A1 | SUBSTITUTED PYRIDO [3', 2': 4, 5] THIENO [3, 2-D] PYRIMIDINES AND PYRIDO [3', 2': 4, 5] FURO [3, 2-D] PYRIMIDINES USED AS INHIBITORS OF THE PDE-4 AND/OR THE RELEASE OF TNF-alpha | CURACYTE DISCOVERY GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| US-20120094987-A1 | SUBSTITUTED PYRIDO [3', 2': 4, 5] THIENO [3, 2-D] PYRIMIDINES AND PYRIDO [3', 2': 4, 5] FURO [3, 2-D] PYRIMIDINES USED AS INHIBITORS OF THE PDE-4 AND/OR THE RELEASE OF TNF-alpha | CURACYTE DISCOVERY GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| US-20120094987-A1 | SUBSTITUTED PYRIDO [3', 2': 4, 5] THIENO [3, 2-D] PYRIMIDINES AND PYRIDO [3', 2': 4, 5] FURO [3, 2-D] PYRIMIDINES USED AS INHIBITORS OF THE PDE-4 AND/OR THE RELEASE OF TNF-alpha | CURACYTE DISCOVERY GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| US-20050009859-A1 | Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2005-01-13 | — | — | US | disclosed |
| US-6841556-B2 | Pyrazoloisoquinoline derivatives for inhibiting NFκB-inducing kinase | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-11 | — | — | US | disclosed |
| US-20040097541-A1 | Pyrazoloisoquinoline derivatives for inhibiting NFkappaB-inducing kinase | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-05-20 | — | — | US | disclosed |
| WO-2004005287-A9 | PYRAZOLOISOQUINOLINE DERIVATIVES FOR INHIBITING NFKAPPAB-INDUCING KINASE (NIK) | AVENTIS PHARMA GMBH (DE) | 2004-03-04 | — | — | WO | disclosed |
| EP-0073502-B1 | METAL COMPLEXES HAVING AN ANTINEOPLASTIC ACTIVITY, AND MEDICAMENTS CONTAINING THESE COMPLEXES | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1986-05-14 | — | — | EP | disclosed |
| WO-1984003042-A1 | PROCESS FOR PRODUCING THERAPEUTICAL ANTINEOPLASTIC PREPARATIONS | BYK GULDEN LOMBERG CHEM FAB (DE) | 1984-08-16 | — | — | WO | disclosed |
| WO-1983000868-A1 | METAL COMPLEXES HAVING AN ANTINEOPLASTIC ACTION, AND MEDICAMENTS CONTAINING THESE COMPLEXES | KELLER, HEIMO, J. | 1983-03-17 | — | — | WO | disclosed |
| EP-0073502-A1 | Metal complexes having an antineoplastic activity, and medicaments containing these complexes | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1983-03-09 | — | — | EP | disclosed |
| US-4082807-A | REACTING AN AROMATIC COMPOUND WITH AN ACETOACETYL FLUORIDE; HYDROGEN FLUORIDE | HOECHST AKTIENGESELLSCHAFT (DT) | 1978-04-04 | — | — | US | disclosed |
| US-3937737-A | CHEMICAL INTERMEDIATES, DYES, PLASTICS, METAL COMPLEXES | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | MAPT 330/4885ALDH1A1 1088/4885SMN1; SMN2 1/4885 |
| US-20040097541-A1 | Pyrazoloisoquinoline derivatives for inhibiting NFkappaB-inducing kinase | NFKBIA, IKBKB, IKBKG | MAPT 1692/4885ALDH1A1 3472/4885SMN1; SMN2 3029/4885 |
| US-20150005289-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | MAPT 207/4885ALDH1A1 1461/4885SMN1; SMN2 1/4885 |
| US-20180105526-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | MAPT 207/4885ALDH1A1 1461/4885SMN1; SMN2 1/4885 |
| US-20120094987-A1 | SUBSTITUTED PYRIDO [3', 2': 4, 5] THIENO [3, 2-D] PYRIMIDINES AND PYRIDO [3', 2': 4, 5] FURO [3, 2-D] PYRIMIDINES USED AS INHIBITORS OF THE PDE-4 AND/OR THE RELEASE OF TNF-alpha | PDE4A, PDE4B, PDE3B | MAPT 3397/4885ALDH1A1 445/4885SMN1; SMN2 2455/4885 |
| US-20050009859-A1 | Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders | PRKDC, MAP3K2, MAP3K20 | MAPT 2944/4885ALDH1A1 3249/4885SMN1; SMN2 1475/4885 |
| US-20170129885-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | MAPT 207/4885ALDH1A1 1461/4885SMN1; SMN2 1/4885 |
| US-11753407-B2 | Compounds for treating spinal muscular atrophy | SMN1; SMN2, CPT1B, GYS1 | MAPT 265/4885ALDH1A1 1651/4885SMN1; SMN2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.